Pascal Amedro1, Adeline Basquin2, Virginie Gressin3, Pierre Clerson4, Xavier Jais5, Jean-Benoit Thambo6, Patrice Guerin7, Sarah Cohen8, Damien Bonnet9. 1. 1Pediatric and Congenital Cardiology,Arnaud de Villeneuve University Hospital,PhyMedexp,INSERM U1046,CNRS UMR 9214,University of Montpellier,Montpellier,France. 2. 3Pediatric and Congenital Cardiology,University Hospital,Rennes,France. 3. 4Actelion Pharmaceuticals France,Paris,France. 4. 5Orgametrie Biostatistics,Roubaix,France. 5. 6Bicêtre University Hospital,Le Kremlin-Bicêtre,France. 6. 7Pediatric and Congenital Cardiology,Haut-Leveque University Hospital,Bordeaux,France. 7. 8Pediatric and Congenital Cardiology,Guillaume and René Laennec University Hospital,Nantes,France. 8. 9Adult Congenital Heart Disease Unit,M3C-George Pompidou European Hospital,AP-HP,Paris Descartes University,France. 9. 11Pediatric and Congenital Cardiology,M3C-Necker University Hospital,AP-HP,Paris Descartes University,Paris, France,France.
Abstract
BACKGROUND: The aim of this study was to assess health-related quality of life in patients with pulmonary arterial hypertension associated with CHD and correlations with clinical status. METHODS: This prospective cross-sectional observational study included CHD patients with pulmonary arterial hypertension in 14 tertiary-care centres in France. We used two health-related quality of life questionnaires - SF-36 and Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) - and one anxiety/depression Hospital Anxiety and Depression Scale (HADS) questionnaire. RESULTS: Clinical data were collected for the 208 included patients (mean age: 42.6 years, range from 15.1 to 85.8 years, 69.7% female). Most patients were in NYHA functional class II (48.1%) and III (37.5%). Patients' phenotype was classified as Eisenmenger syndrome (70.7%), pulmonary arterial hypertension associated with systemic-to-pulmonary shunts (12.0%), with small defects (3.4%), or after corrective cardiac surgery (13.9%). In total, 76.4% of the patients were receiving pulmonary arterial hypertension-specific treatments. SF-36 scores showed impairment compared with normalised data. Health-related quality of life scores were significantly lower in females than in males for most dimensions of both questionnaires and were independent of the patients' phenotype, even after gender adjustment - except for CAMPHOR functioning - but significantly depended on NYHA functional class. The Hospital Anxiety and Depression Scale (HADS) scores suggested anxiety and depression associated with increasing NYHA functional class but independent of patients' phenotype. NYHA functional class, 6-minute walk distance, HADS, gender, and recent stressful event significantly affected quality of life in the multivariate analysis. CONCLUSIONS: This study showed impairment of quality of life in a large cohort of patients with pulmonary arterial hypertension associated with CHD with both generic and specific questionnaires. NYHA functional class and HADS scores were predictive of most quality of life scores.
BACKGROUND: The aim of this study was to assess health-related quality of life in patients with pulmonary arterial hypertension associated with CHD and correlations with clinical status. METHODS: This prospective cross-sectional observational study included CHD patients with pulmonary arterial hypertension in 14 tertiary-care centres in France. We used two health-related quality of life questionnaires - SF-36 and Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) - and one anxiety/depression Hospital Anxiety and Depression Scale (HADS) questionnaire. RESULTS: Clinical data were collected for the 208 included patients (mean age: 42.6 years, range from 15.1 to 85.8 years, 69.7% female). Most patients were in NYHA functional class II (48.1%) and III (37.5%). Patients' phenotype was classified as Eisenmenger syndrome (70.7%), pulmonary arterial hypertension associated with systemic-to-pulmonary shunts (12.0%), with small defects (3.4%), or after corrective cardiac surgery (13.9%). In total, 76.4% of the patients were receiving pulmonary arterial hypertension-specific treatments. SF-36 scores showed impairment compared with normalised data. Health-related quality of life scores were significantly lower in females than in males for most dimensions of both questionnaires and were independent of the patients' phenotype, even after gender adjustment - except for CAMPHOR functioning - but significantly depended on NYHA functional class. The Hospital Anxiety and Depression Scale (HADS) scores suggested anxiety and depression associated with increasing NYHA functional class but independent of patients' phenotype. NYHA functional class, 6-minute walk distance, HADS, gender, and recent stressful event significantly affected quality of life in the multivariate analysis. CONCLUSIONS: This study showed impairment of quality of life in a large cohort of patients with pulmonary arterial hypertension associated with CHD with both generic and specific questionnaires. NYHA functional class and HADS scores were predictive of most quality of life scores.
Authors: Debasree Banerjee; Sara E Vargas; Kate M Guthrie; Brittany M Wickham; Melissa Allahua; Mary E Whittenhall; Amy J Palmisciano; Corey E Ventetuolo Journal: Pulm Circ Date: 2018 Oct-Dec Impact factor: 3.017
Authors: Hamouda Abassi; Helena Huguet; Marie-Christine Picot; Marie Vincenti; Sophie Guillaumont; Annie Auer; Oscar Werner; Gregoire De La Villeon; Kathleen Lavastre; Arthur Gavotto; Pascal Auquier; Pascal Amedro Journal: Health Qual Life Outcomes Date: 2020-11-12 Impact factor: 3.186
Authors: Aaron Shengting Mai; Oliver Zi Hern Lim; Yeung Jek Ho; Gwyneth Kong; Grace En Hui Lim; Cheng Han Ng; Cyrus Ho; Roger Ho; Yinghao Lim; Ivandito Kuntjoro; Edgar Tay; James Yip; Nicholas W S Chew; Ting-Ting Low Journal: Front Med (Lausanne) Date: 2022-02-17